RxDoctor Payments Data

Lakshya Chandra, MD

Hospitalist · Washington, DCNPI 1336580802

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Boston Scientific at 34.3% of the total. Reporting peaked in 2019 at $159 and has fallen 86.5% since, to $22 in 2024.

$357in general payments, 2019–2025

Across 16 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$123
  • Johnson & Johnson$121
  • Inari Medical, Inc.$41
  • Novartis$22
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$22
  • AstraZeneca$15
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$357100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$357 in reported general payments places this provider in the 85th percentile of 101 hospitalist providers in District of Columbia.

See all hospitalist providers in District of Columbia

Medicare billing

Part B allowed, 2024
$102,781
Medicare patients
400
Services billed
917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$15,819
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,382
Albuterol Sulfate HfaAlbuterol Sulfate21$963
Pantoprazole Sodium71$686
Atorvastatin Calcium52$398
Cefdinir28$230
Diltiazem 24hr Er (Cd)Diltiazem Hcl11$151
Levetiracetam11$145
Doxycycline Hyclate25$142
Metoprolol Succinate25$120
Amlodipine Besylate33$116
Furosemide36$114
Finasteride14$112
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15$111
Levothyroxine Sodium15$103

Paid to pharmacies, not to this prescriber.

Other hospitalist in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →